The presence of donor specific antibodies predisposes the thoracic allograft to the risk of antibody mediated rejection, chronic graft dysfunction and increased mortality. Optimal outcomes depend upon a comprehensive understanding of the significance of circulating antibodies after transplantation. What are the best strategies for defining deleterious antibodies, what are the current available therapies to address these and how effective are they?
After participating in this webinar, the learner will be able to:
Identify the significance of circulating antibodies in patients awaiting thoracic transplantation or in patients with development of de novo antibodies after transplantation.
Order appropriate tests to detect relevant donor specific antibodies.